Literature DB >> 29028633

Acute kidney injury in congenital heart disease.

Katja M Gist1, David M Kwiatkowski2, David S Cooper3.   

Abstract

PURPOSE OF REVIEW: Acute kidney injury (AKI) is associated with significant morbidity and mortality in patients with congenital heart disease undergoing cardiac surgery or in pediatric patients with congestive heart failure. RECENT
FINDINGS: This review describes the definition and various manifestations of AKI, the impact of biomarkers on the diagnosis of AKI, the importance of fluid overload as a consequence of AKI and its long-term impact.
SUMMARY: There are novel biomarkers for AKI detection that should facilitate early recognition and intervention to prevent or attenuate the effects of AKI and fluid overload. Previous conventional wisdom that survivors of AKI fully recover renal function without subsequent consequences is flawed.

Entities:  

Mesh:

Year:  2018        PMID: 29028633     DOI: 10.1097/HCO.0000000000000473

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  3 in total

1.  Variation in clinical usefulness of biomarkers of acute kidney injury in young children undergoing cardiac surgery.

Authors:  Hee Sun Baek; Youngok Lee; Hea Min Jang; Joonyong Cho; Myung Chul Hyun; Yeo Hyang Kim; Su-Kyeong Hwang; Min Hyun Cho
Journal:  Clin Exp Pediatr       Date:  2020-02-05

Review 2.  Biomarkers of acute kidney injury in pediatric cardiac surgery.

Authors:  Candice Torres de Melo Bezerra Cavalcante; Marcelo Borges Cavalcante; Klebia Magalhães Pereira Castello Branco; Titus Chan; Isabel Cristina Leite Maia; Ronald Guedes Pompeu; Andrea Consuelo de Oliveira Telles; Anna Karina Martins Brito; Alexandre Braga Libório
Journal:  Pediatr Nephrol       Date:  2021-05-25       Impact factor: 3.714

3.  A meta-analysis of the incidence rate of postoperative acute kidney injury in patients with congenital heart disease.

Authors:  Dandan Li; Zhaozhuo Niu; Qiang Huang; Wei Sheng; Tianyi Wang
Journal:  BMC Nephrol       Date:  2020-08-17       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.